Last week I attended Pennsylvania BIO's CEO Roundtable event, where Cephalon's Frank Baldino, Prism Pharmaceuticals' Warren Cooper and Fujirebio Diagnostics' Paul Touhey spoke to a room packed with the biotech industry's rank-and-file. They shared their thoughts on drug development, generic biologics, the current economic environment and managing biotech talent. Here's what they had to say. Article